|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||76.71 - 77.70|
|52 Week Range||63.76 - 89.54|
|PE Ratio (TTM)||21.91|
|Forward Dividend & Yield||2.28 (2.95%)|
|1y Target Est||N/A|
Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.
After being the only one to finish 2016 in the red, the healthcare sector made a comeback in 2017 and finished the year up 21.7%, barely lagging the S&P 500’s (SPX) 21.83% increase. It’s still early in ...
Let's see if Gilead Sciences Inc. (GILD) stock is a good choice for value-oriented investors right now from multiple angles.
The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech exchange traded fund by assets, tumbled alongside the broader market in February. In fact, IBB’s February loss surpassed those ...
Shares of Gilead Sciences Inc (NASDAQ:GILD) will begin trading ex-dividend in 3 days. To qualify for the dividend check of $0.57 per share, investors must have owned the shares priorRead More...
If you are interested in cashing in on Gilead Sciences Inc’s (NASDAQ:GILD) upcoming dividend of $0.57 per share, you only have 5 days left to buy the shares before itsRead More...
Based on readouts from this study, the company plans to evaluate the efficacy and safety of once-a-week semaglutide therapy in NASH indications in its Phase 3 trial. According to a Diabetes Care report, ~80% of NASH patients suffer from obesity.